NEUROGENE INC (NGNE)
(Delayed Data from NSDQ)
$32.50 USD
-0.71 (-2.14%)
Updated May 10, 2024 04:00 PM ET
After-Market: $32.59 +0.09 (0.28%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Neurogene Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 56 | 59 | 61 | 34 | 71 |
Income After Depreciation & Amortization | -56 | -59 | -61 | -34 | -71 |
Non-Operating Income | 19 | 2 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -36 | -58 | -61 | -33 | -69 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -36 | -58 | -61 | -33 | -69 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -36 | -58 | -61 | -33 | -69 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -57 | -58 | -32 | -71 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 2 | 2 | 0 |
Income After Depreciation & Amortization | -56 | -59 | -61 | -34 | -71 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 2.76 | 2.75 | 2.59 | 1.35 |
Diluted EPS Before Non-Recurring Items | NA | -20.80 | -22.00 | -15.80 | -15.00 |
Diluted Net EPS (GAAP) | -7.80 | -20.80 | -22.00 | -12.80 | -51.40 |
Fiscal Year end for Neurogene Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 35.23 | 5.57 | 3.06 | 15.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -35.23 | -5.57 | -3.06 | -15.14 |
Non-Operating Income | NA | 16.32 | 1.04 | 0.98 | 0.93 |
Interest Expense | NA | 0.01 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -15.50 | -4.53 | -2.09 | -14.20 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -15.50 | -4.53 | -2.09 | -14.20 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -15.50 | -4.53 | -2.09 | -14.20 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 2.78 | 2.81 | 2.77 |
Diluted EPS Before Non-Recurring Items | NA | NA | -1.64 | -0.80 | -4.00 |
Diluted Net EPS (GAAP) | NA | -0.16 | -1.64 | -0.80 | -5.20 |